ICLUSIG® patient-profiles

William

High resistance

T315I mutation

No history of CV events

Meet William

35-year-old construction worker who owns his own business
He has 2 children and runs regularly to stay fit for his annual charity race

Clinical background

Diagnosed with CP-CML 54 months ago and became resistant to 1L dasatinib after 54 months
T315I mutation was detected at 54 months
His BCR::ABL1^IS level is 4%
His ELTS score is low
William is a former smoker, but has no previous history of CV events

William was responding to 1L dasatinib until his BCR::ABL1^IS level increased to >1% at 54 months

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known BCR::ABL1 resistance single mutations, including T315I^1–4

ELN recommendations (2020) note that ICLUSIG is the only TKI with activity against the T315I mutant, and recommend ICLUSIG in patients with T315I, unless CV risk factors preclude its use⁵

View William's Full Profile

Agnes

High resistance

V299L mutation

Dyslipidaemia (well controlled)

Meet Agnes

68-year-old recently retired paramedic
She volunteers to teach first-aid classes and is looking forward to her son’s wedding

Clinical background

Diagnosed with CP-CML 48 months ago and became resistant to 1L dasatinib after 48 months
V299L mutation was detected at 48 months
Her BCR::ABL1^IS level is 3%
Her ELTS score is intermediate
Agnes has a family history of dyslipidaemia and, after lifestyle changes were ineffective, was recently prescribed statins to balance her lipid levels

Agnes was responding to 1L dasatinib until her BCR::ABL1^IS level increased to 3% at 48 months

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known BCR::ABL1 resistance single mutations, including V299L^1–3

View Agnes' Full Profile

Francine

High resistance

No mutation detected

No history of CV events

Meet Francine

69-year-old retired nurse
She likes to stay active and is a member of her local walking club

Clinical background

Diagnosed with CP-CML 33 months ago and became resistant to 1L imatinib at 24 months and 2L dasatinib at 33 months
Her BCR::ABL1^IS level is 8% and she has no mutations detected
Her ELTS score is low
Francine has no history of CV events

Francine was responding to 2L dasatinib until her BCR::ABL1^IS level increased to 8% at 33 months

The most frequent mechanisms of resistance in CP-CML are BCR::ABL1-independent⁶

ELN recommendations (2020) note that patients who are resistant to a 2G TKI without specific mutations should preferably be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use⁵

View Francine's Full Profile

Thomas

Low resistance

E255K mutation

No history of CV events

Meet Thomas

66-year-old biology teacher
He walks his dog regularly with his family and will become a grandfather next year

Clinical background

Diagnosed with CP-CML 60 months ago and became resistant to 1L nilotinib after 60 months
E255K mutation was detected at 60 months
His BCR::ABL1^IS level is 10%
His ELTS score is low
Thomas has no history of CV events

Thomas was responding to 1L nilotinib until 60 months when his BCR::ABL1^IS level increased to 10%

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known single BCR::ABL1 resistance mutations, including E255K^1–3

View Thomas' Full Profile

Martha

Low resistance

F317L mutation

Hypertension and hypercholesterolaemia
(both well controlled)

Meet Martha

65-year-old semi-retired café worker
She lives with her daughter and is looking forward to their holiday abroad together

Clinical background

Diagnosed with CP-CML 42 months ago and became resistant to 1L imatinib at 24 months and 2L dasatinib at 42 months
F317L mutation was detected at 42 months
Her BCR::ABL1^IS level is 12%
Her ELTS score is intermediate
Martha takes beta blockers and statins to keep her hypertension and hypercholesterolaemia under control

Martha’s BCR::ABL1^IS level demonstrated an initial response to 1L imatinib and 2L dasatinib. However, results at 36 and 42 months confirmed rising BCR::ABL1^IS levels

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known single BCR::ABL1 resistance mutations, including F317L^1–3

View Martha's Full Profile

Maria

Intolerant

No history of TKI resistance

Hypertension (well controlled)

Meet Maria

67-year-old museum curator
Maria and her husband enjoy spending quality time together when gardening

Clinical background

Was diagnosed with CP-CML 6 months ago, and became intolerant to 1L bosutinib due to diarrhoea, 2L dasatinib due to pleural effusion and 3L imatinib due to muscle cramps
Her BCR::ABL1^IS level is 0.04% and she has no known mutations
Her ELTS score is intermediate
Maria is prescribed an ACE inhibitor and calcium channel blocker to manage her hypertension and her BMI is 31.0 kg/m²

Maria’s BCR::ABL1^IS level is responding to 3L imatinib

Approximately 25% of patients with CML change TKIs because of adverse events. We know that cycling TKIs may lead to mutations, lowering the likelihood of response to an alternative TKI^4,7,8

ELN recommendations (2020) suggest starting ICLUSIG at a lower dose in the case of intolerance to previous TKIs⁵

View Maria's Full Profile

Peter

Intolerant

No history of TKI resistance

No history of CV events

Meet Peter

52-year-old journalist
He is an amateur photographer and is excited for his next travelling adventure

Clinical background

Diagnosed with CP-CML 62 months ago, becoming resistant to 1L imatinib after 60 months and developing intolerance to 2L dasatinib after 2 months of treatment
His BCR::ABL1^IS level is 0.09% after 2 months of dasatinib treatment
His ELTS score is low
He has no BCR::ABL1 mutations or previous history of CV events
Peter has some gastrointestinal issues following treatment with dasatinib but no other comorbidities

Peter’s BCR::ABL1^IS level is 0.09% after 2 months of 2L dasatinib treatment

Approximately 25% of patients with CML change TKIs because of adverse events. We know that cycling TKIs may lead to mutations, lowering the likelihood of response to an alternative TKI^4,7,8

ELN recommendations (2020) suggest starting ICLUSIG at a lower dose in the case of intolerance to previous TKIs⁵

View Peter's Full Profile

Interested in exploring how patients with CP-CML who are eligible may benefit from ICLUSIG?

Download all 7 ICLUSIG Patient Profiles

Abbreviations: 1L, first line; 2G, second generation; 2L, second line; ACE, angiotensin-converting enzyme; BMI, body mass index; CML, chronic myeloid leukaemia; CP, chronic phase; CV, cardiovascular; ELN, European LeukemiaNet; ELTS, EUTOS Long-Term Survival; EUTOS, European Treatment and Outcome Study; IS, international scale; TKI, tyrosine kinase inhibitor.

References: 1. ICLUSIG^® (ponatinib). Summary of Product Characteristics. Incyte. 2022; 2. O’Hare T, et al. Cancer Cell. 2009;16:401–12; 3. Kantarjian HM, et al. Am J Hematol. 2022;97:1419–26; 4. Cortes J, Lang F. J Hematol Oncol. 2021;14:44; 5. Hochhaus A, et al. Leukemia. 2020;34:966–84; 6. De Santis S, et al. Onco Targets Ther. 2022;15:103–16; 7. Claudiani S, et al. Leukemia. 2024;38:796–802; 8. Braun TP, et al. Cancer Cell. 2020;37:530–42.

William

William

Meet William

Clinical background

William was responding to 1L dasatinib until his BCR::ABL1IS level increased to >1% at 54 months

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known BCR::ABL1 resistance single mutations, including T315I1–4

View William's Full Profile

Agnes

Agnes

Meet Agnes

Clinical background

Agnes was responding to 1L dasatinib until her BCR::ABL1IS level increased to 3% at 48 months

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known BCR::ABL1 resistance single mutations, including V299L1–3

View Agnes' Full Profile

Francine

Francine

Meet Francine

Clinical background

Francine was responding to 2L dasatinib until her BCR::ABL1IS level increased to 8% at 33 months

The most frequent mechanisms of resistance in CP-CML are BCR::ABL1-independent6

View Francine's Full Profile

Thomas

Thomas

Meet Thomas

Clinical background

Thomas was responding to 1L nilotinib until 60 months when his BCR::ABL1IS level increased to 10%

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known single BCR::ABL1 resistance mutations, including E255K1–3

View Thomas' Full Profile

Martha

Martha

Meet Martha

Clinical background

Martha’s BCR::ABL1IS level demonstrated an initial response to 1L imatinib and 2L dasatinib. However, results at 36 and 42 months confirmed rising BCR::ABL1IS levels

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known single BCR::ABL1 resistance mutations, including F317L1–3

View Martha's Full Profile

Maria

Maria

Meet Maria

Clinical background

Maria’s BCR::ABL1IS level is responding to 3L imatinib

Approximately 25% of patients with CML change TKIs because of adverse events. We know that cycling TKIs may lead to mutations, lowering the likelihood of response to an alternative TKI4,7,8

View Maria's Full Profile

Peter

Peter

Meet Peter

Clinical background

Peter’s BCR::ABL1IS level is 0.09% after 2 months of 2L dasatinib treatment

Approximately 25% of patients with CML change TKIs because of adverse events. We know that cycling TKIs may lead to mutations, lowering the likelihood of response to an alternative TKI4,7,8

View Peter's Full Profile

Interested in exploring how patients with CP-CML who are eligible may benefit from ICLUSIG?

William was responding to 1L dasatinib until his BCR::ABL1^IS level increased to >1% at 54 months

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known BCR::ABL1 resistance single mutations, including T315I^1–4

Agnes was responding to 1L dasatinib until her BCR::ABL1^IS level increased to 3% at 48 months

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known BCR::ABL1 resistance single mutations, including V299L^1–3

Francine was responding to 2L dasatinib until her BCR::ABL1^IS level increased to 8% at 33 months

The most frequent mechanisms of resistance in CP-CML are BCR::ABL1-independent⁶

Thomas was responding to 1L nilotinib until 60 months when his BCR::ABL1^IS level increased to 10%

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known single BCR::ABL1 resistance mutations, including E255K^1–3

Martha’s BCR::ABL1^IS level demonstrated an initial response to 1L imatinib and 2L dasatinib. However, results at 36 and 42 months confirmed rising BCR::ABL1^IS levels

ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all known single BCR::ABL1 resistance mutations, including F317L^1–3

Maria’s BCR::ABL1^IS level is responding to 3L imatinib

Approximately 25% of patients with CML change TKIs because of adverse events. We know that cycling TKIs may lead to mutations, lowering the likelihood of response to an alternative TKI^4,7,8

Peter’s BCR::ABL1^IS level is 0.09% after 2 months of 2L dasatinib treatment

Approximately 25% of patients with CML change TKIs because of adverse events. We know that cycling TKIs may lead to mutations, lowering the likelihood of response to an alternative TKI^4,7,8